We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.75 | -12.24% | 5.375 | 5.00 | 5.75 | 6.25 | 5.125 | 6.25 | 2,495,017 | 12:44:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.20 | 6.18M |
TIDMGDR
RNS Number : 8702R
Genedrive PLC
19 June 2018
For release: 19 June 2018
genedrive plc ("genedrive" or the "Company")
Additional Listing of Shares
Genedrive plc announces that it has issued 93,669 ordinary 1.5p shares in the capital of the Company ("Ordinary Shares") to settle shares owing under the Epistem Share Incentive Plan.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 25 June 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
Following admission, the Company's issued share capital will comprise 18,783,115 Ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 18,873,115. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV ID Kit and Genedrive(R) platform in India.
Further details can be found at: www.genedriveplc.com and www.genedrive.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ALSUKARRWNANAAR
(END) Dow Jones Newswires
June 19, 2018 06:18 ET (10:18 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions